Experimental Study of Heart Functionality during Treatment of Chronic Heart Failure in Rats of Different Age Groups with Levosimendan (Experimental Study)

2020 ◽  
Vol 169 (1) ◽  
pp. 18-23
Author(s):  
M. L. Mamalyga ◽  
L. M. Mamalyga
Keyword(s):  
Heart Failure ◽  
Experimental Study ◽  
Chronic Heart Failure ◽  
Age Groups

Transcheter aortic valve implantation as a method of treatment of chronic heart failure in elderly and old patients: Literature review (part 1)

2022 ◽  
pp. 901-909
Author(s):  
К. Л. Козлов ◽  
А.Н. Богомолов ◽  
Е.И. Сенькина ◽  
Н.Г. Лукьянов ◽  
Л.В. Башкатова ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Aortic Valve ◽  
Transcatheter Aortic Valve Implantation ◽  
Age Groups ◽  
Interventional Cardiology ◽  
Old Patients ◽  
Transcatheter Aortic Valve ◽  
Aortic Valve Implantation ◽  
Valve Implantation

Стеноз аортального клапана (АК) - самое частое приобретенное клапанное заболевание с растущей распространенностью из-за старения населения, требующее хирургического или эндоваскулярного вмешательства. Транскатетерная имплантация АК (Transcatheter Aortic Valve Implantation, TAVI) представляет собой настоящую революцию в области интервенционной кардиологии для лечения пациентов старческого возраста или из группы высокого риска с тяжелым симптомным стенозом АК. TAVI позволяет выполнять коррекцию аортального порока наиболее тяжелой группе больных ХСН с выраженной коморбидностью, которым противопоказано выполнение открытой операции по замене АК, для прерывания порочного круга в прогрессировании ХСН, стимуляции обратного ремоделирования миокарда, облегчения симптомов, улучшения качества жизни и прогноза больных, а также в качестве «моста» к трансплантации сердца. Благодаря разработке устройств нового поколения, TAVI превратилась из сложной и опасной процедуры в эффективную и безопасную методику. Наибольший научный интерес в настоящее время представляет изучение долговечности клапана и возможности расширения показаний к выполнению TAVI у категорий пациентов с низким хирургическим риском, а также более молодого возраста. Aortic valve (AV) stenosis is the most common acquired valvular disease with an increasing prevalence due to an aging population, requiring surgical or endovascular intervention. Transcatheter Aortic Valve Implantation (TAVI) represents a real revolution in the field of interventional cardiology for the treatment of elderly or high-risk patients with severe symptomatic AV stenosis. TAVI allows for the correction of aortic defect in the most severe group of patients with chronic heart failure (CHF) with severe comorbidity, who are contraindicated for open surgery to replace AV, in order to interrupt the vicious circle in the progression of CHF, stimulate reverse myocardial remodeling, alleviate symptoms, improve the quality of life, and prognosis of patients, and also as a «bridge» to heart transplantation. With the development of next-generation devices, TAVI has evolved from a complex and dangerous procedure to an effective and safe technique. Currently, the greatest scientific interest is the study of valve durability and the possibility of expanding the indications for performing TAVI in categories of patients with low surgical risk, as well as in younger age groups.

Chronic heart failure

2020 ◽  
pp. 217-240
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Mortality Rate ◽  
Adult Population ◽  
Age Groups ◽  
Severe Heart Failure ◽  
Signs And Symptoms ◽  
Developed Countries ◽  
Clinical Syndrome ◽  
The Uk

Heart failure is a complex clinical syndrome of signs and symptoms that suggest the ability of the heart to pump effectively has been impaired. It is distinguished by dyspnoea, effort intolerance, fluid retention, and poor survival. The prevalence of heart failure is around 1–2% in the adult population in developed countries, and 920 000 people in the UK have heart failure. The incidence of heart failure has decreased; however, the number of people newly diagnosed with heart failure has increased. This is thought to be largely due to an ageing population, improvement in the management and survival of people with ischaemic heart disease, and effective treatment of heart failure. The condition can occur in all age groups; however, the incidence and prevalence steeply increase with age. The average age at first diagnosis is typically 77yrs. Chronic heart failure (CHF) has a poor prognosis, the mortality rate for CHF being worse than for many cancers. It is estimated that 70% of those hospitalized for the first time with severe heart failure will die within 5yrs. However, this has been improving, with 6mth mortality rate ↓ from 26% in 1995, 15% in 2009, to 8.9% in 2016. This chapter will outline the aetiology, pathophysiology, and management of CHF, including considerations for palliative care.

Prevalence, Sex and Age Peculiarities of Chronic Heart Failure among Rural and Urban Population of the North-Ossetia-Alania

10.12737/7266 ◽  
2014 ◽  
Vol 21 (4) ◽  
pp. 40-44
Author(s):  
Дедегкаева ◽  
T. Dedegkaeva ◽  
Астахова ◽  
Z. Astakhova
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Urban Areas ◽  
Urban Population ◽  
Clinical Symptoms ◽  
Age Groups ◽  
Epidemiological Studies ◽  
The North ◽  
Rural And Urban ◽  
North Ossetia

Chronic heart failure is one of the most common diseases of the cardiovascular system. It is known that the Russian epidemiological studies on the chronic heart failure are significantly different from the overseas, but at the same time it revealed differences between individual regions of the Russian Federation. A set of material was held on the basis of six medical institutions of the Republic of North Ossetia-Alania, selected as a result of the randomization. 688 families, including 1600 respondents aged from18 to 100 years of rural and urban population of North Ossetia-Alania, were examined. The diagnosis of chronic heart failure was verified on the basis of a standardized assessment of clinical symptoms used in the study of EPOCH- CHF. The prevalence of heart failure among the rural population of the North Ossetia-Alania was slightly higher and reached 14.4% , and 13.9 % in urban areas. Among both rural and urban popula-tion of the North Ossetia-Alania the prevalence of heart failure was high, more than a few times higher than international epidemiological studies and higher than epidemiological research data of EPOCH - CHF. Severe сhronic heart failure reached 3.8% in rural and 3.9 % in urban population of the entire representative sample. The prevalence of сhronic heart failure was 1.3 times higher in women than in men. Among younger age groups, the prevalence of heart failure was higher in men than in women.

Microviscosity of erythrocyte membranes during chronic heart failure in patients of middle and senior age groups

2015 ◽  
Vol 5 (2) ◽  
pp. 89-93
Author(s):  
T. Yu. Rebrova ◽  
S. A. Afanasiev ◽  
O. D. Putrova ◽  
A. N. Repin
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Age Groups ◽  
Erythrocyte Membranes

scholarly journals “Rehospitalization Prognostic Factors In Patients with Heart Failure”

2021 ◽  
Vol 8 (10) ◽  
pp. 5676-5682
Author(s):  
Helal Ahmed ◽  
Mahmud Chowdhury ◽  
Lira Saha
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Cox Regression ◽  
Age Groups ◽  
Clinical Signs ◽  
Functional Class ◽  
Independent Effect ◽  
Leading Role ◽  
And Gender

Introduction: The prognosis of chronic heart failure (CHF) is determined by the complex relationship of neurohormonal, mechanical and polyorgan pathological changes emerging in the course and progression of the disease. Objective:  To assess the risk and rate of rehospitalisation due to decompensation of chronic heart failure (CHF) in relation to certain biologic, clinical and instrumental characteristics. Material and Methods: This study conducted in the Department of Cardiology, Community Based Medical College & Hospital, Bangladesh. Prospective study on 228 consecutive CHF patients. The follow-up period was 12 to 24 months. The primary endpoint was rehospitalization due to HF decompensation. The risk values were calculated using the Cox regression models.   Results: Median survival time was 8 months. The total number of rehospitalizations was 86 (37.7%).  Rehospitalization risk values were insignificantly lower in women (HR 0.7, 95% CI 0.4-1.1, р >0.05) and higher in older age groups (HR 1.4 95% CI 0.8-2.2, р>0.05). Univariate regression analysis showed a higher rehospitalization risk in patients with survived myocardial infarction, clinical signs of CHF, high functional class and pulmonary pressure. Multivariate regression analyses revealed the leading role of functional class on rehospitalization risk.   Conclusion: rehospitalization rates due to decompensation of CHF are high. Age and gender are insignificant predictors for rehospitalization in our study. Functional class is the prognostic factor with an independent effect on rehospitalization risk over the defined follow-up period among the examined group of patients. 

Experimental study on effect mechanism of Shen Cao Tongmai Granule on rats with chronic heart failure

2019 ◽  
Vol 6 ◽  
pp. S142
Author(s):  
Yue Liu ◽  
Fan Zhang ◽  
Zhen Hua ◽  
Yang Zhang ◽  
Ying Chen ◽  
...  
Keyword(s):  
Heart Failure ◽  
Experimental Study ◽  
Chronic Heart Failure ◽  
Effect Mechanism

scholarly journals Pathophysiologic aspects of the development of cognitive disorders in chronic heart failure in elderly patients

2018 ◽  
Vol 99 (2) ◽  
pp. 260-264 ◽  
Author(s):  
M A Pokachalova ◽  
M V Silyutina
Keyword(s):  
Heart Failure ◽  
Cerebral Ischemia ◽  
Chronic Heart Failure ◽  
Elderly Patients ◽  
Cognitive Dysfunction ◽  
Age Groups ◽  
Cognitive Disorders ◽  
Chronic Cerebral Ischemia ◽  
Course Of Disease

The present literature review presents current views on pathophysiologic aspects of the formation and progression of cognitive disorders in chronic heart failure in elderly patients. Advanced age itself is an important predictor of the development of cardiovascular, neurodegenerative and other diseases. Involutive changes of cardiovascular system are known to potentiate the development of chronic heart failure. Heart failure in older people usually develops gradually. Formation of the cognitive deficit in heart disease is associated with chronic cerebral ischemia as well as a cascade of neurochemical processes occurring in the brain, eventually forming a vicious circle. Often the symptoms of cerebral ischemia due to reduced stroke volume occur much earlier than congestion signs in other organs and systems. Chronic cerebral ischemia that occurs due to violation of cerebral hemodynamics, is associated with both extracerebral and intracerebral causes, which in turn contributes to the development of chronic brain hypoxia and aggravation of cognitive dysfunction. Thus, the features of the development and course of disease in people of older age groups indicate that in geriatric practice existing diagnostic schemes are not always applicable. When observing patients of elderly and senile age with chronic heart failure, during the assessment of their condition and running diagnostic tests, special attention should be payed to the earliest detection of cognitive dysfunction signs in order to correct the patient's treatment and improve quality of life.

Chronic heart failure

2014 ◽  
pp. 193-212
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Mortality Rate ◽  
Poor Prognosis ◽  
Age Groups ◽  
Severe Heart Failure ◽  
Clinical Syndrome ◽  
Coronary Syndromes ◽  
The Uk ◽  
First Time

Heart failure is a clinical syndrome distinguished by dyspnoea, effort intolerance, fluid retention, and poor survival. Although the management of acute coronary syndromes (ACS) has improved, with a resultant decrease in mortality, the numbers of people who subsequently go on to develop chronic heart failure (CHF) are increasing. The prevalence of heart failure is around 2–3% in the overall population and approximately 900 000 people in the UK have heart failure. It is estimated that there will be an increase in prevalence of 50% in the next 20 years, attributed to better outcomes for CHF. The condition can occur in all age groups, however the incidence and prevalence steeply increases with age. The average age at first diagnosis is typically 76, with the prevalence in the 70–80 age groups, rising to between 10–20%. CHF has a poor prognosis, the mortality rate for CHF being worse than for many cancers. It is estimated that 70% of those hospitalized for the first time with severe heart failure will die within 5 years. However, this has been improving, with 6-month mortality rate decreasing from 26% in 1995, to 14% in 2005. This chapter outlines the aetiology, pathophysiology, and management of CHF, including considerations for palliative care.

Sign in / Sign up

Export Citation Format

Share Document